Physician Views snap poll: Are HIV prescribers ready for two drug treatment regimens?

The GlaxoSmithKline led ViiV Healthcare is hoping so.

It recently secured approval of its second two drug regimen in HIV; Dovato (dolutegravir/lamivudine) for use in adults with HIV-1 infection with no prior history of antiretroviral therapy and no known resistance to its individual components.

What’s more, longer term data - the latest published earlier this month - appears supportive of two-drug regimen use. Do prescribers agree?

We are snap-polling US based specialists with the following questions…

__________

Q. The FDA has approved Dovato (dolutegravir/lamivudine) for use in adults with HIV-1 infection with no prior history of antiretroviral therapy and no known resistance to its individual components. In the Phase III GEMINI 1 and 2 trials, Dovato demonstrated similar efficacy to the three-drug combination of Tivicay (dolutegravir) and Truvada (tenofovir disoproxil fumarate/emtricitabine) in treatment-naïve adults with HIV-1.

Labelling includes a boxed warning which stipulates "patients infected with both HIV and hepatitis B should add additional treatment for their hepatitis B or consider a different drug regimen."

At launch, Dovato has been priced at a 26 percent discount versus Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)

Based on your current knowledge of this regimen, approximately how many newly diagnosed patients would you expect to be prescribing Dovato to in 12 months’ time?

-

Q. To what extent will your use of Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) limit your adoption of Dovato (dolutegravir/lamivudine)?

None

Marginal impact

Moderate impact

Significant impact

-

Q. Recently presented three year results from the SWORD 1 and 2 studies demonstrate that 84 percent (432/513) of participants who switched from their current three- or four-drug antiretroviral regimen to a different 2-drug regimen of dolutegravir and rilpivirine - marketed as Juluca - maintained viral suppression (viral load ≤50 copies/mL). Discontinuations due to adverse events were reported in six percent of patients and confirmed virologic withdrawals in one percent. No patients developed resistance to dolutegravir, and only 6 to rilpivirine.

How compelling are these data as supporting current/future use of two drug regimens?

Not compelling

Slightly compelling

Moderately compelling

Very compelling

-

Q. Do you think the potential lower toxicity of a two-drug regimen outweighs the possible risk of a lower barrier to disease resistance?

Strongly disagree

Disagree

Neither disagree/agree

Agree

Strongly agree

-

Q. Do you think more of your newly diagnosed HIV patients would prefer to be on a two drug regimen versus a three drug regimen?

Strongly disagree

Disagree

Neither disagree/agree

Agree

Strongly agree

__________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.